Recombinant Clostridium difficile Toxin Fragments as Carrier Protein for PSII Surface Polysaccharide Preserve Their Neutralizing Activity

Recent Mechanistic Insights on Glycoconjugate Vaccines and Future Perspectives

(2013) Francesco Berti et al.   ACS Chemical Biology

Carbohydrate-based Clostridium difficile vaccines

(2013) Mario A Monteiro et al.   Expert Review of Vaccines

Protective Efficacy Induced by Recombinant Clostridium difficile Toxin Fragments

(2013) Rosanna Leuzzi et al.   INFECTION AND IMMUNITY

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile

(2013) R. G. K. Donald et al.   MICROBIOLOGY-SGM

Epidemiology of Community-AssociatedClostridium difficileInfection, 2009 Through 2011

(2013) Amit S. Chitnis et al.   JAMA Internal Medicine

Phosphorylation of the Synthetic Hexasaccharide Repeating Unit Is Essential for the Induction of Antibodies to Clostridium difficile PSII Cell Wall Polysaccharide

(2012) Roberto Adamo et al.   ACS Chemical Biology

Clostridium difficile carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual C. difficile–ETEC conjugate vaccine

(2012) Lisa Bertolo et al.   CARBOHYDRATE RESEARCH

Structural characterization of surface glycans from Clostridium difficile

(2012) Christopher W. Reid et al.   CARBOHYDRATE RESEARCH

Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain

(2012) Laurica A. Petrella et al.   CLINICAL INFECTIOUS DISEASES

Immunization strategies forClostridium difficileinfections

(2012) Fabien Rebeaud et al.   Expert Review of Vaccines

Multiple Factors Modulate Biofilm Formation by the Anaerobic Pathogen Clostridium difficile

(2012) T. Thapa et al.   JOURNAL OF BACTERIOLOGY

Antibody Against TcdB, but Not TcdA, Prevents Development of Gastrointestinal and Systemic Clostridium difficile Disease

(2012) Jennifer Steele et al.   JOURNAL OF INFECTIOUS DISEASES

Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies

(2012) Andre J. Marozsan et al.   JOURNAL OF INFECTIOUS DISEASES

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models

(2012) Jing-Hui Tian et al.   VACCINE

Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines and other potential clinical applications

(2011) Michael Bröker et al.   BIOLOGICALS

A Possible Oligosaccharide-Conjugate Vaccine Candidate for Clostridium difficile Is Antigenic and Immunogenic

(2011) Matthias A. Oberli et al.   CHEMISTRY & BIOLOGY

The design of semi-synthetic and synthetic glycoconjugate vaccines

(2011) Paolo Costantino et al.   Expert Opinion on Drug Discovery

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Synthesis ofC. difficilePS-II Cell Wall Polysaccharide Repeating Unit

(2010) Elisa Danieli et al.   ORGANIC LETTERS

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)

(2009) Brett A. Leav et al.   VACCINE

Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units

(2008) Jeyabarathy Ganeshapillai et al.   CARBOHYDRATE RESEARCH

Clostridium difficile— More Difficult Than Ever

(2008) Ciarán P. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE